A Phase 1, Open-label, Single Dose Study to Evaluate the Concentration of RE104 and Its Major Metabolites in Breast Milk and Plasma of Healthy Lactating Women
Latest Information Update: 21 Dec 2024
Price :
$35 *
At a glance
- Drugs RE-104 (Primary)
- Indications Postnatal depression
- Focus Pharmacokinetics
- Sponsors Reunion Neuroscience
- 11 Dec 2024 According a Reunion Neuroscience media release, a poster detailing RE104 Phase 1 data presented at the American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting in Phoenix, Arizona.
- 19 Nov 2024 Status changed from not yet recruiting to recruiting.
- 30 Oct 2024 New trial record